Michael Grey Joins Mirati Therapeutics Board of Directors
SAN DIEGO, Nov. 6, 2014 /PRNewswire/ --- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.
"Mike's extensive experience in the pharmaceutical and biotechnology industries, including senior leadership and board positions in several successful companies, will complement and strengthen our Board," said Charles M. Baum, M.D. Ph.D., president and CEO of Mirati. "His expertise in developing strategy, identifying growth opportunities and building organizations is invaluable as we advance our targeted oncology medicines to the market."